- Home
- ZBAO vs BOLD Comparison
ZBAO vs BOLD Comparison
Compare ZBAO & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBAO
- BOLD
- Stock Information
- Founded
- ZBAO 2015
- BOLD 2018
- Country
- ZBAO China
- BOLD United States
- Employees
- ZBAO N/A
- BOLD N/A
- Industry
- ZBAO
- BOLD
- Sector
- ZBAO
- BOLD
- Exchange
- ZBAO NYSE
- BOLD Nasdaq
- Market Cap
- ZBAO 48.7M
- BOLD 49.5M
- IPO Year
- ZBAO 2024
- BOLD 2024
- Fundamental
- Price
- ZBAO $1.17
- BOLD $1.45
- Analyst Decision
- ZBAO
- BOLD Buy
- Analyst Count
- ZBAO 0
- BOLD 3
- Target Price
- ZBAO N/A
- BOLD $22.50
- AVG Volume (30 Days)
- ZBAO 19.7K
- BOLD 85.1K
- Earning Date
- ZBAO 11-04-2024
- BOLD 03-27-2025
- Dividend Yield
- ZBAO N/A
- BOLD N/A
- EPS Growth
- ZBAO N/A
- BOLD N/A
- EPS
- ZBAO 0.06
- BOLD N/A
- Revenue
- ZBAO $25,274,784.00
- BOLD N/A
- Revenue This Year
- ZBAO $65.08
- BOLD N/A
- Revenue Next Year
- ZBAO $34.27
- BOLD N/A
- P/E Ratio
- ZBAO $19.32
- BOLD N/A
- Revenue Growth
- ZBAO 29.25
- BOLD N/A
- 52 Week Low
- ZBAO $1.06
- BOLD $1.42
- 52 Week High
- ZBAO $5.70
- BOLD $14.18
- Technical
- Relative Strength Index (RSI)
- ZBAO N/A
- BOLD N/A
- Support Level
- ZBAO N/A
- BOLD N/A
- Resistance Level
- ZBAO N/A
- BOLD N/A
- Average True Range (ATR)
- ZBAO 0.00
- BOLD 0.00
- MACD
- ZBAO 0.00
- BOLD 0.00
- Stochastic Oscillator
- ZBAO 0.00
- BOLD 0.00
About ZBAO ZHIBAO TECHNOLOGY INC
Zhibao Technology Inc is a insurance technology company engaged in providing digital insurance brokerage services in China. 2B2C digital embedded insurance is their business model which is pioneered in China. It provides customized digital insurance solutions for B-side channels (covering a wide range of industries and organizations, including but not limited to Internet platforms, large and medium-sized enterprises, and government agencies, etc.), embedding them into the channel's existing business matrix, and providing the channel with Provide digital insurance brokerage services to C-end customers.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.